Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease

Redenšek Trampuž, Sara (author), Flisar, Dušan (author), Kojović, Maja (author), Gregorič Kramberger, Milica (author), Georgiev, Dejan (author), Pirtošek, Zvezdan (author), Trošt, Maja (author), Dolžan, Vita (author)

Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson's disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic pathway genes on the occurrence of motor and non-motor adverse events of dopaminergic treatment in Parkinson's disease. In total, 231 Parkinson's disease patients were enrolled. Demographic and clinical data were collected. Genotyping was performed for 16 single nucleotide polymorphisms from key dopaminergic pathway genes. Logistic and Cox regression analyses were used for evaluation. Results were adjusted for significant clinical data. We observed that carriers of at least one COMT rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; p = 0.004), while carriers of at least one DRD3 rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; p = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; p = 0.008, respectively). Carriers of at least one DDC rs921451 C allele and CT heterozygotes had higher odds for orthostatic hypotension (OR = 1.86; 95% CI = 1.07-3.23; p = 0.028 and OR = 2.30; 95% CI = 1.26-4.20; p = 0.007, respectively). Heterozygotes for DDC rs3837091 and SLC22A1 rs628031 AA carriers also had higher odds for orthostatic hypotension (OR = 1.94; 95% CI = 1.07-3.51; p = 0.028 and OR = 2.57; 95% CI = 1.11-5.95; p = 0.028, respectively). Carriers of the SLC22A1 rs628031 AA genotype had higher odds for peripheral edema and impulse control disorders (OR = 4.00; 95% CI = 1.62-9.88; p = 0.003 and OR = 3.16; 95% CI = 1.03-9.72; p = 0.045, respectively). Finally, heterozygotes for SLC22A1 rs628031 and carriers of at least one SLC22A1 rs628031 A allele had lower odds for dyskinesia (OR = 0.48; 95% CI = 0.24-0.98, p = 0.043 and OR = 0.48; 95% CI = 0.25-0.92; p = 0.027, respectively). Gene-gene interactions, more specifically DDC-COMT, SLC18A2-SV2C, and SLC18A2-SLC6A3, also significantly influenced the occurrence of some adverse events. Additionally, haplotypes of COMT and SLC6A3 were associated with the occurrence of visual hallucinations (AT vs. GC: OR = 0.34; 95% CI = 0.16-0.72; p = 0.005) and orthostatic hypotension (ATG vs. ACG: OR = 2.48; 95% CI: 1.01-6.07; p = 0.047), respectively. Pathway based approach allowed us to identify new potential candidates for predictive biomarkers of adverse events of dopaminergic treatment in Parkinson's disease, which could contribute to treatment personalization.

• Language: English
• Keywords: Parkinson's disease, genetic polymorphism, dopaminergic pathway, personalized medicine, adverse events
• Work type: Article
• Typology: 1.01 - Original Scientific Article
• Organization: MF - Faculty of Medicine
• Publication status: Published
• Publication version: Version of Record
• Year: 2019
• Number of pages: 10 str.
• Numbering: Vol. 10, art. 8
• PID: 20.500.12556/RUL-128756
• UDC: 615
• ISSN on article: 1663-9812
• DOI: 10.3389/fphar.2019.00008
• COBISS.SI-ID: 34173401
• Publication date in RUL: 27.07.2021

REDENŠEK TRAMPUŽ, Sara, FLISAR, Dušan, KOJOVIĆ, Maja, GREGORIČ KRAMBERGER, Milica, GEORGIEV, Dejan, PIRTOŠEK, Zvezdan, TROŠT, Maja and DOLŽAN, Vita, 2019, Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson’s disease. Frontiers in pharmacology [online]. 2019. Vol. 10,  8. [Accessed 18 March 2025]. DOI 10.3389/fphar.2019.00008. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=128756

Record is a part of a journal

• Title: Frontiers in pharmacology
• Shortened title: Front. pharmacol.
• Publisher: Frontiers Media
• ISSN: 1663-9812
• COBISS.SI-ID: 29551833

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
• Licensing start date: 28.01.2019

Secondary language

• Language: Slovenian
• Keywords: Parkinsonova bolezen, genetski polimorfizem, dopaminergično zdravljenje, personalizirana medicina, škodljivi dogodki

Projects

• Funder: ARRS - Slovenian Research Agency
• Project number: P1-0170
• Name: Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

• Funder: ARRS - Slovenian Research Agency
• Funding programme: Grant for young researchers